Page 61 - Read Online
P. 61

Page 346                              Genvigir et al. J Transl Genet Genom 2020;4:320-55  I  http://dx.doi.org/10.20517/jtgg.2020.37


                     Ref.   [25]  [72]   [74]         [13]       [71]     [73]       [29]  [27]

                        No association of IMPDH1 rs2228075   variant with AR  IMPDH1 rs2278294 A allele was   increased risk of leukopenia  No association of rs2278293 with AR,  leukopenia, CMV and other infections No direct association of IMPDH1  variants with subclinical AR.  with high MPA night-time exposure  range (AUC > 60 µg.h⁄mL and C 0   ≥ 1.9 µg/mL) was associated with   subclinical AR No association of IMPDH1 variants  with MPA-related AR or leukopenia  The vari


                     Clinical outcomes   associated with reduced risk of AR and   IMPDH1 rs2278293 A allele combined   with MMF doses tolerated (1 year) and   with AR, graft function (1 year) or graft   with AR, leukopenia anemia or diarrhea   IMPDH1 rs2228075 G and rs2278294












                    Immunosuppressive   regimen  One-year follow-up  One-year follow-up  One-year follow-up  One-year follow-up   One-year follow-up  EC-MPS, Cyclosporine  Six-month follow-up  One-year follow-up






                        MMF  Cyclosporine  Corticosteroids  MMF  Cyclosporine  Tacrolimus  Corticosteroids  MMF  Tacrolimus  Corticosteroids  At day 28  MMF  Cyclosporine  Tacrolimus  mTOR inhibitor   Corticosteroids  MMF  Tacrolimus  Prednisone   MMF  Cyclosporine  Tacrolimus  Corticosteroids  Corticosteroids  MMF  Tacrolimus  Cyclosporine  Sirolimus  Corticosteroids




                     Population   237 adult patients  456 adult patients   82 adult patients (Japan)  218 adult patients (France)  191 adult patients (USA)   1,040 adult patients  189 adult patients   284 pediatric and young   adult patients (USA)




                 Table 3. Genes related to mycophenolic acid pharmacodynamics in kidney transplantation




                     Study design  Prospective, multicenter   (CAESAR study)  Prospective, multicenter   (Apomygre and FDCC   studies)  Prospective  Retrospective (Transgene   study)   Retrospective  Prospective, multicenter  (Collaborative Transplant   study)   Prospective, multicenter   (Dominos study)  Retrospective (Case-  control), multicenter









                     Allele frequency  c.1320A: 22%  rs2278293 A: 46%  rs2278294 A: 36%  rs2278293 A: 44%  rs2278294 A: 45%  rs2278293 A: 49%  rs2278294 A: 38%  rs2228075 T: 25%  rs2278293 A: 43%  rs2278294 A: 40%  rs2278293 T: 45%  rs2278294 A: 40%  rs2278923 T: 47%  rs2278924 T: 33%  rs2228075: -  rs2278293: -  rs2278294: -











                        rs2228075 C>T   (Ala525Ala,   c.1320G>A)  rs2278293 C>T   (c.579+119G>A)  rs2278294 C>T   (c.580-106G>A)
                     Variant





                     Gene   IMPDH1
   56   57   58   59   60   61   62   63   64   65   66